Status: Exited/Public

Antios Therapeutics

Posted on November 3, 2021 by -

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Jasper Therapeutics

Posted on October 12, 2021 by -

Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.

Merged with Amplitude Healthcare Acquisition Corporation in 2021

Caribou Biosciences

Posted on July 13, 2021 by -

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Arch Oncology

Posted on July 13, 2021 by -

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

Posted on July 13, 2021 by -

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Sentynl Therapeutics

Posted on July 13, 2021 by -

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017

Eyevance Pharmaceuticals

Posted on July 13, 2021 by -

Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.

Acquired by Santen in 2020